The biopharmaceutical company focuses on oncology and uses its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform to develop cancer therapies using the toxin Amanitin. Its lead candidate is HDP-101, a BCMA-ATAC for multiple myeloma. In addition to drug development, the company offers preclinical contract research services in explorative pharmacology, drug metabolism and pharmacokinetics analysis, and molecular biology for oncology or inflammatory/autoimmune diseases. Heidelberg Pharma GmbH serves the pharmaceutical and biotechnology industries through its business divisions: Customer Specific Research, Diagnostics, and Therapeutics.